Niraparib + pegylated liposomal doxorubicin

Niraparib + pegylated liposomal doxorubicin is an investigational combination therapy for cancer treatment, particularly ovarian cancer. Niraparib is a potent and selective small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes PARP-1 and PARP-2. By inhibiting these enzymes involved in DNA repair pathways—especially base excision repair—niraparib induces synthetic lethality in tumor cells with homologous recombination deficiency (such as those with BRCA mutations)[6][1]. Pegylated liposomal doxorubicin is a formulation of the anthracycline chemotherapeutic agent doxorubicin encapsulated in PEG-coated liposomes to enhance tumor targeting and reduce toxicity[3][5][8]. Doxorubicin works by intercalating DNA and inhibiting topoisomerase II activity[5]. The combination aims to exploit synergistic cytotoxicity by simultaneously impairing DNA repair (via PARP inhibition) and inducing DNA damage (via topoisomerase II inhibition), potentially improving efficacy while managing toxicity profiles[1].

Brand names

Doxil

Other names

PARP inhibitor + anthracycline liposome combination